Transaction #21484 · Form 4 · 0001193125-25-323090
Kymera Therapeutics, Inc. · Exercise / conversion · Common Stock
Kymera Therapeutics, Inc. · Transacted December 17, 2025 · Filed December 17, 2025
What does this filing report?
An SEC Form 4 filing for Kymera Therapeutics, Inc. records an exercise / conversion involving Common Stock on December 17, 2025. The reported quantity was 3,000. The filing date is December 17, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Kymera Therapeutics, Inc.
- Company CIK
- 0001815442
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 3,000
- Reported price
- 31.2
- Reference value
- 93,600
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 27,563
- Ownership description
- Not reported
- SEC acceptance time
- Dec 17, 2025, 6:07 PM EST
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Esposito Pamela ↗
Director
CIK 0001744425
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person.
- F2
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.99 to $81.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.99 to $82.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.99 to $83.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.99 to $84.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6
- The shares underlying this stock option are fully vested and exercisable.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.